← Back to Browse

AstraZeneca PLC

AZN • Healthcare

92
Grade A
Compass
Current Price
$187.72
Market Cap
$544.0B

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Quality Assessment

AstraZeneca PLC is a high-quality healthcare company with a Compass Score of 92. This stock demonstrates strong fundamentals across profitability, cash flow, and stability metrics. Suitable for long-term investors seeking quality.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
21
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Growth Projections

Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

Financial Health

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.